Onconova Therapeutics Is Looking to Spearhead the Next Drug Development Wave With Its Ongoing Trial

A look at how the company is trying to use the Ras oncogne to tackle leukemiaRelated Stocks: ONTX,.....»»

Category: worldSource: nytJan 12th, 2018

Mersana Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates

Enrollment on Track for Phase 1 Trial of XMT-1522 Patients with Advanced Tumors Expressing HER2 Progressing Phase 1 Trial of XMT-1536, First-in-Class Dolaflexin® Antibody Drug Conjugate Targeting Na.....»»

Category: earningsSource: benzingaMar 28th, 2018

Edge Therapeutics"s stock plummets on heavy volume after late-stage drug trial discontinued

Shares of Edge The.....»»

Category: topSource: marketwatchMar 28th, 2018

Cidara Therapeutics" stock soars toward 13-month high after positive drug trial results

Shares of Cidara Therapeutics Inc. shot up 14% toward a 13-month high in premarket .....»»

Category: topSource: marketwatchMar 19th, 2018

Voyager Therapeutics (VYGR) Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced Parkinson"s Disease - Slideshow

Voyager Therapeutics (VYGR) Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced Parkinson"s Disease - Slideshow.....»»

Category: topSource: seekingalphaMar 9th, 2018

Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2017 Financial Results

NEWTOWN, Pa., March 08, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug.....»»

Category: earningsSource: benzingaMar 8th, 2018

7 Biotech Stocks With Clinical Trial Outcomes In March

Development of a drug is a tedious, time-consuming and expensive process, with the journey of the drug from the lab to the pharmacy shelf usually taking around 12 years. read more.....»»

Category: blogSource: benzingaMar 5th, 2018

Aimmune shares surge 10% on positive late-stage trial results for peanut allergy drug

Aimmune Therapeutics Inc. shares rose 9.8% in premarket trade Tuesday after the company said a late-stage trial for its peanut allergy drug met its primary endpoint. The company pl.....»»

Category: topSource: marketwatchFeb 20th, 2018

Seattle Genetics buys Cascadian Therapeutics for $614 million

Cascadian has been doubling down on its lead drug candidate, Tucatinib, currently in a Phase 2 drug trial for treating advanced breast cancer......»»

Category: topSource: bizjournalsJan 31st, 2018

The hottest thing in cancer drug development is a takeover target again — here"s what you need to know about it (JUNO, CELG)

AP Biotech giant Celgene is in talks to acquire Juno Therapeutics, The Wall Street Journal reported on Tuesday. If the deal goes through, it'd be the second deal in the past few months for companies working on treatments that.....»»

Category: topSource: businessinsiderJan 17th, 2018

Is Cara Therapeutics, Inc. a Buy?

Is a setback in a trial of its only clinical drug a warning to stay away from this little biotech?.....»»

Category: topSource: foxnewsDec 18th, 2017

Here"s Why Marinus Pharmaceuticals Rose as Much as 41.1% Thursday

What happened Shares of clinical stage biopharma Marinus Pharmaceuticals NASDAQ MRNS rose over 41 today after larger peer Sage Therapeutics NASDAQ SAGE reported positive top line results for one of its drug candidates SAGE 217 in a phase 2 trial in major.....»»

Category: futuresSource: nasdaqDec 7th, 2017

Could Sage Therapeutics’ Depression Drug Be the Next Big Thing?

Sage Therapeutics saw its shares make an incredible gain on Thursday after the firm announced positive top-line results from its midstage trial......»»

Category: blogSource: 247wallstDec 7th, 2017

Charting the Market: Sage Therapeutics Could Cure Your Blues

In a mid-phase study of an antidepressant under development by Sage Therapeutics, the novel drug worked faster and more effectively than currently-marketed treatments......»»

Category: blogSource: barronsDec 7th, 2017

With latest drug trial, Sage catapults into top 5 most valuable Mass. biotechs

Sage Therapeutics saw its market cap jump more than $2.5 billion on Thursday after announcing that one of its depression drugs had aced a mid-stage trial, vaulting the Cambridge-based company into the state’s top five most valuable biotechs. Sag.....»»

Category: topSource: bizjournalsDec 7th, 2017

Brace for a Coming Wave of Cancer-Drug Trial Failures: Gadfly

Brace for a Coming Wave of Cancer-Drug Trial Failures: Gadfly.....»»

Category: topSource: washpostNov 28th, 2017

Acorda Therapeutics crashes 40% after patients die in drug trial (ACOR)


Category: topSource: businessinsiderNov 15th, 2017

Sage Therapeutics to seek approval of postpartum depression drug after trial win

Cambridge biotech Sage Therapeutics says it plans to apply for U.S. approval of its experimental drug to treat postpartum depression next year after the drug achieved the main goals in two late-stage trials involving more than 200 women. Sage (Na.....»»

Category: topSource: bizjournalsNov 9th, 2017

Global Blood Therapeutics stock declines after forsaking half its drug pipeline

After investing millions in research and development, the company said the drug didn’t work well enough to keep going......»»

Category: topSource: marketwatchOct 23rd, 2017

What"s Behind Celldex Therapeutics, Inc."s 16% Rally in September?

It looks like impatient investors anticipating news from an ongoing pivotal trial drove up the stock last month......»»

Category: topSource: foxnewsOct 6th, 2017

Halozyme Therapeutics Wins Big on Roche License Agreement

Halozyme Therapeutics saw its shares make a handy gain early on Thursday after the firm announced that it licensed its Enhanze drug-delivery technology to Roche for exclusive development of an........»»

Category: blogSource: 247wallstSep 14th, 2017